Company: CMND
Filing Date: 2025-10-27
Form Type: 6-K
Source: 0001213900-25-102378
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-10-27
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Attached hereto and incorporated herein is the
Registrant’s press release issued on October 27, 2025, titled “Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief
of Global Impact to Advance US Partnerships and Governmental Engagement”.

The first, second, fifth and sixth paragraphs of
the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements
on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293)
and Form S-8 (File No. 333-283695),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit No. |     |                                                                                                                                                             |
| 99.1        |     | Press release titled: “Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement” |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: October 27, 2025 | Clearmind Medicine, Inc. 
 (Registrant)             
 By:                      | /s/ Adi Zul